X
Xianzhong Bai
Researcher at Guangxi Medical University
Publications - 4
Citations - 99
Xianzhong Bai is an academic researcher from Guangxi Medical University. The author has contributed to research in topics: Sunitinib & Sorafenib. The author has an hindex of 4, co-authored 4 publications receiving 54 citations.
Papers
More filters
Journal ArticleDOI
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Ai Ping Zhou,Yuxian Bai,Yan Song,Hong Luo,Xiu Bao Ren,Xiuwen Wang,Benkang Shi,Cheng Fu,Ying Cheng,Ji-Yan Liu,Shukui Qin,Jun Li,Hanzhong Li,Xianzhong Bai,Dingwei Ye,Jinwan Wang,Jianhui Ma +16 more
TL;DR: The clinical efficacy of anlotinib was similar to that of sunitinib as the first-line treatment for mRCC, but with a more favorable safety profile.
Journal ArticleDOI
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
Jianhui Ma,Yan Song,Jianzhong Shou,Yuxian Bai,Hanzhong Li,Xiaodong Xie,Hong Luo,Xiubao Ren,Ji-Yan Liu,Dingwei Ye,Xianzhong Bai,Cheng Fu,Shukui Qin,Jinwan Wang,Aiping Zhou +14 more
TL;DR: Anlotinib showed promising efficacy as well as favorable safety as second-line treatment for patients with mRCC as assessed in a single-arm, open-label, phase 2 study.
Journal ArticleDOI
Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial.
Aiping Zhou,Yuxian Bai,Yan Song,Hangzhong Li,Xiaodong Xie,Xiubao Ren,Dingwei Ye,Ji-Yan Liu,Hong Luo,Xianzhong Bai,Shukui Qin,Cheng Fu,Jinwan Wang,Jianhui Ma +13 more
TL;DR: FGF signaling regulates tumor growth and vascularization and partly mediates antiangiogenic escape from VEGFR inhibitors and Sequential TKI treatment has shown encouraging results in FGF-naïve mice.
Journal ArticleDOI
Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.
Aiping Zhou,Jianhui Ma,Yuxian Bai,Yan Song,Hangzhong Li,Xiaodong Xie,Xiubao Ren,Dingwei Ye,Ji-Yan Liu,Hong Luo,Xianzhong Bai,Shukui Qin,Cheng Fu,Jinwan Wang +13 more
TL;DR: Anlotinib is a potent oral, small molecular TKI with a favorable safety profile in phase I clinical trial which mainly targets VEGFR1/2/3, FGFR2.